Drug ads must show prices. Here's what changes for patients.
H.R. 4623 — Plain Prescription Prices Act · Filed by Nikema Williams (D-GA) · 4 cosponsors · Introduced Jul 22, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Centers for Medicare & Medicaid Services to write rules, within one year, mandating that direct-to-consumer TV ads for prescription drugs and biologics covered by Medicare or Medicaid display the list price for a typical 30-day supply or course of treatment in clear, truthful text. The agency must also decide whether to extend the rule to other ad formats, set the display format, establish enforcement, and determine if additional pricing details should be included.
Why we flagged it
The bill's sole operative mechanism is a regulatory mandate requiring disclosure of drug pricing in advertisements. It is a transparency and consumer-protection measure, not a subsidy, carve-out, or industry favor.
What the text implies
- Pharmaceutical companies may respond by reducing direct-to-consumer advertising volume or shifting spend to formats not yet covered by the rule, potentially limiting consumer awareness of treatment options.
- List price disclosure without context (rebates, copay assistance, patient programs) may mislead consumers into believing out-of-pocket costs match list price, requiring CMS to define what 'truthful' means in subsection (b)(4).
- The rule applies only to drugs covered by Medicare/Medicaid, creating a two-tier ad landscape where non-covered drugs remain price-opaque, potentially disadvantaging uninsured or commercially-insured patients seeking price information.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Consumers gain transparent pricing information at the point of marketing exposure, enabling more informed conversations with doctors and pharmacists about drug costs and alternatives. This addresses a documented information asymmetry where ads promote drugs without disclosing price, shifting purchasing pressure onto patients without their knowledge of cost.
Named in the bill
Centers for Medicare & Medicaid Services (CMS), Secretary of Health and Human Services, Medicare (Title XVIII, Social Security Act), Medicaid (Title XIX, Social Security Act), Pharmaceutical industry (subject to disclosure requirement, not beneficiary)
Where it stands
4 cosponsors: 3 Republicans, 1 Democrats.
- Jul 22, 2025 — Introduced · Congress.gov: “Introduced in House”
- Jul 22, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,010,000 in lobbying spend. A filing names 77 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Nikema Williams, the sponsor, reported $431,250 in PAC receipts in the 2026 cycle.
- America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,426 characters) on Sep 28, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Drug ads must show prices. Here's what changes for patients.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr4623 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.